pamidronate has been researched along with Anemia, Cooley's in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "All patients had osteopenia, diminished osteoid formation and bone volume on histomorphometry pre-therapy with high turnover bone disease (HTO) in TM and low-turnover disease (LTO) in TI." | 6.77 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. ( Bajoria, R; Byers, M; Chatterjee, R; Davis, BA; Porter, JB; Pringle, J; Shah, FT; Sooranna, D, 2012) |
| "One of the most common complications in thalassemia major patients is osteopenia and osteoporosis." | 5.43 | Which pamidronate protocol is the best for treating osteoporosis in beta-thalassemia major? ( Kowsaryan, M; Zafari, M, 2016) |
| "Osteoporosis is characterized by low bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility." | 3.01 | Treatment for osteoporosis in people with beta-thalassaemia. ( Bhardwaj, A; Sinha, NK; Swe, KMM, 2023) |
| "All patients had osteopenia, diminished osteoid formation and bone volume on histomorphometry pre-therapy with high turnover bone disease (HTO) in TM and low-turnover disease (LTO) in TI." | 2.77 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. ( Bajoria, R; Byers, M; Chatterjee, R; Davis, BA; Porter, JB; Pringle, J; Shah, FT; Sooranna, D, 2012) |
| "One of the most common complications in thalassemia major patients is osteopenia and osteoporosis." | 1.43 | Which pamidronate protocol is the best for treating osteoporosis in beta-thalassemia major? ( Kowsaryan, M; Zafari, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhardwaj, A | 1 |
| Swe, KMM | 1 |
| Sinha, NK | 1 |
| Kowsaryan, M | 1 |
| Zafari, M | 1 |
| Skordis, N | 1 |
| Ioannou, YS | 1 |
| Kyriakou, A | 1 |
| Savva, SC | 1 |
| Efstathiou, E | 1 |
| Savvides, I | 1 |
| Christou, S | 1 |
| Chatterjee, R | 1 |
| Shah, FT | 1 |
| Davis, BA | 1 |
| Byers, M | 1 |
| Sooranna, D | 1 |
| Bajoria, R | 1 |
| Pringle, J | 1 |
| Porter, JB | 1 |
| Voskaridou, E | 1 |
| Terpos, E | 1 |
| Spina, G | 1 |
| Palermos, J | 1 |
| Rahemtulla, A | 1 |
| Loutradi, A | 1 |
| Loukopoulos, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Denosumab Versus Zoledronic Acid for Patients With Beta-Thalassemia Major-Induced Osteoporosis[NCT03040765] | Phase 3 | 17 participants (Actual) | Interventional | 2018-05-14 | Terminated (stopped due to failed to recruit eligible subjects) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pamidronate and Anemia, Cooley's
| Article | Year |
|---|---|
Treatment for osteoporosis in people with beta-thalassaemia.
Topics: Adult; Alendronate; beta-Thalassemia; Child; Clodronic Acid; Denosumab; Diphosphonates; Female; Frac | 2023 |
2 trials available for pamidronate and Anemia, Cooley's
| Article | Year |
|---|---|
Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Topics: Absorptiometry, Photon; Adult; Alendronate; beta-Thalassemia; Bone Density; Bone Density Conservatio | 2008 |
Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabo | 2012 |
2 other studies available for pamidronate and Anemia, Cooley's
| Article | Year |
|---|---|
Which pamidronate protocol is the best for treating osteoporosis in beta-thalassemia major?
Topics: Adult; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Respon | 2016 |
Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
Topics: Acid Phosphatase; Adult; Alkaline Phosphatase; Anti-Inflammatory Agents; beta-Thalassemia; Biomarker | 2003 |